Matt Gline (L) and Vivek Ramaswamy

Vivek Ra­maswamy and Matt Gline pen share­hold­er let­ters about the changes now un­der­way at Roivant

Friends and col­leagues,

I am writ­ing to pro­vide our an­nu­al up­date on Roivant. These up­dates are usu­al­ly re­strict­ed to our share­hold­ers, but we are shar­ing this year’s let­ter more broad­ly to an­nounce an up­com­ing change in my role from CEO to Ex­ec­u­tive Chair­man and the pro­mo­tion of Matt Gline to Chief Ex­ec­u­tive Of­fi­cer.

Re­flec­tions on 2020

Much has tran­spired in the world and at our com­pa­ny since my last an­nu­al up­date in Jan­u­ary 2020. One year ago we had just com­plet­ed our $3 bil­lion trans­ac­tion with Sum­it­o­mo Dainip­pon Phar­ma (DSP), and we were eval­u­at­ing how to rein­vest in our busi­ness. At the same time, SARS-CoV-2 was still a dis­tant virus bare­ly on our minds. To­day it has af­flict­ed the en­tire world spar­ing lit­er­al­ly no one from its ef­fects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA